Mylan Laboratories (MYL) Levothyroxine Sodium Tablets USP Approved as Generic Equivalent to Levothroid
Up)
Mylan Laboratories Inc. (NYSE: MYL) announced that the U.S. Food and Drug Administration (FDA) has granted the company approval to market its currently approved Levothyroxine Sodium Tablets, USP as a bioequivalent and, therefore, therapeutically equivalent product to Levothroid Tablets (manufactured by Lloyd Pharmaceuticals for Forest Laboratories Inc. (NYSE: FRX)).
Total U.S. sales for all Levothyroxine brands and generic equivalents were approximately $1 billion for the 12-month period ended Sept. 30, 2006, according to data from IMS Health.
Total U.S. sales for all Levothyroxine brands and generic equivalents were approximately $1 billion for the 12-month period ended Sept. 30, 2006, according to data from IMS Health.
You May Also Be Interested In
- Mylan (MYL) Unit Launches Generic Viramune Tabs
- IsoRay (ISR) Says GliaSite System Received CE Mark; to Go On Sale in 31 European Markets
- Celldex (CLDX) volatility up into conference call to announce EMERGE results
Create E-mail Alert Related Categories
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
